Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
J Anim Sci ; 92(11): 5203-13, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25349362

RESUMO

The objectives of this study were to 1) quantify effects of metaphylactic treatment for bovine respiratory disease (BRD) on growth performance, carcass characteristics, and lung lesion prevalence and severity; 2) evaluate the association of lung lesion prevalence and severity with carcass characteristics; and 3) evaluate effects of therapeutic treatment on carcass characteristics and lung lesion prevalence and severity. The study was conducted at a commercial feedlot in the Texas Panhandle in which steers (n = 2,336) initially weighing 312.1 ± 9.6 kg were sourced from auction markets and allocated in a randomized complete block design to 1 of 3 treatments (no metaphylactic [no antimicrobial drug {ND}] treatment, tilmicosin at 10 mg/kg BW [TIL], and tulathromycin at 2.5 mg/kg BW [TUL]). Lungs of all steers were evaluated during harvest to assess presence and severity of pneumonic lesions in the anteroventral lobes and the presence and severity of pleural adherences. Compared to the ND treatment, steers treated via metaphylactic therapy had greater (P < 0.05) metaphylactic cost, ADG, shrunk final BW, dressed carcass yield, HCW, 12th rib fat, calculated empty body fat (EBF), and gross revenue, concurrent with reduced (P < 0.05) BRD treatment costs and financial losses from BRD death and railed cattle, cumulatively resulting in greater financial returns. Lung lesions were present in 64.3% of lungs and were distributed similarly between metaphylactic treatments (63.9%) and ND (65.1%) cattle. Steers with advanced lung lesions present at harvest were associated with reduced (P < 0.05) HCW, KPH, 12th rib fat, calculated yield grades, marbling scores, and calculated EBF as compared to steers without lung lesions. Steers pulled for BRD had increased (P < 0.01) incidence of advanced lung lesions, mortality, and railers with decreased (P < 0.05) HCW, 12th rib fat, KPH, marbling score, calculated EBF, and percentage choice carcasses when compared to non-BRD event steers. From the results of this study, controlling BRD through the use of metaphylactic treatments on arrival in heavier cattle improved financial returns primarily driven by reductions in cost of death loss and railers.


Assuntos
Composição Corporal/efeitos dos fármacos , Complexo Respiratório Bovino/epidemiologia , Bovinos/crescimento & desenvolvimento , Dissacarídeos/uso terapêutico , Compostos Heterocíclicos/uso terapêutico , Tilosina/análogos & derivados , Tecido Adiposo/efeitos dos fármacos , Animais , Antibacterianos/economia , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Antibioticoprofilaxia/veterinária , Complexo Respiratório Bovino/economia , Complexo Respiratório Bovino/prevenção & controle , Análise Custo-Benefício , Dissacarídeos/economia , Dissacarídeos/farmacologia , Compostos Heterocíclicos/economia , Compostos Heterocíclicos/farmacologia , Pulmão/patologia , Masculino , Prevalência , Distribuição Aleatória , Índice de Gravidade de Doença , Texas , Resultado do Tratamento , Tilosina/economia , Tilosina/farmacologia , Tilosina/uso terapêutico
2.
J Anim Sci ; 92(3): 1219-27, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24492552

RESUMO

This research was designed to evaluate the effect of monensin (Elanco Animal Health, Greenfield, IN) supplementation via mineral or pressed protein block with or without a growth-promoting implant on performance of steers grazing wheat pasture in Arkansas over 2 yr. Preconditioned steers (n = 360, BW = 238 ± 5.1 kg) grazed 15 1.6-ha wheat pastures in the fall (n = 60 steers each fall, stocking rate of 2.5 steers/ha) or 30 0.8-ha wheat pastures in the spring (n = 120 steers each spring, stocking rate of 5 steers/ha). Steers in each pasture were given free-choice access to nonmedicated mineral (CNTRL; MoorMan's WeatherMaster Range Minerals A 646AAA; ADM Alliance Nutrition, Inc., Quincy, IL), or were supplemented with monensin (Elanco Animal Health, Greenfield, IN) via mineral containing 1.78 g monensin/kg (RMIN; MoorMan's Grower Mineral RU-1620 590AR; ADM Alliance Nutrition, Inc.), or pressed protein block containing 0.33 g monensin/kg (RBLCK; MoorMan's Mintrate Blonde Block RU; ADM Alliance Nutrition, Inc.). Additionally, one-half of the steers in each pasture were implanted (IMPL) with 40 mg trenbolone acetate and 8 mg estradiol (Component TE-G with Tylan; Elanco Animal Health). There was no interaction (P ≥ 0.71) between supplement treatment and growth-promoting implants, and ADG for RMIN and RBLCK were increased (P < 0.01) over CNTRL by 0.07 to 0.09 kg/d, respectively. Implanting steers with Component TE-G increased (P < 0.01) ADG by 0.14 kg/d. The combination of these growth-promoting technologies are a cost-effective means of increasing beef production by 22% without increasing level of supplementation or pasture acreage. Utilizing ionophores and implants together for wheat pasture stocker cattle decreased cost of gain by 26%. Utilizing both IMPL and monensin increased net return by $30 to $54/steer for RMIN or $18 to $43/steer for RBLCK compared with UNIMPL CNTRL at Low and High values of BW gain, respectively.


Assuntos
Ração Animal/análise , Criação de Animais Domésticos , Bovinos/crescimento & desenvolvimento , Dieta/veterinária , Monensin/farmacologia , Triticum/química , Anabolizantes/administração & dosagem , Anabolizantes/farmacologia , Fenômenos Fisiológicos da Nutrição Animal , Animais , Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Implantes de Medicamento , Estradiol/administração & dosagem , Estradiol/farmacologia , Estrogênios/administração & dosagem , Estrogênios/farmacologia , Masculino , Estações do Ano , Acetato de Trembolona/administração & dosagem , Acetato de Trembolona/farmacologia , Tilosina/administração & dosagem , Tilosina/farmacologia
3.
J Dairy Res ; 77(4): 404-10, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20822561

RESUMO

Non-specific (innate) immune response plays a major role in defending the udder from bacterial invasion. Moreover, recent investigations suggest that mammary gland epithelial cells (MGEC) could have a large and important role as a source of soluble components of immune defences. Despite many attempts to find other ways to control/prevent mastitis (i.e. vaccine) antimicrobial therapy is still the most used and effective means of curing clinical and subclinical mastitis. However, drug concentrations and therapy durations are far from the optimal in order to reduce costs. Therefore, efficacy of antimicrobial therapy is dependent not only on the substance activity but also on the positive interactions with the host innate immune response. Surprisingly, information on these interactions is rather scarce in the mastitis field. A simple experimental model was developed based on BME-UV cell line, Staphylococcus aureus as a challenge and a macrolide as an antimicrobial to assess the interactions among epithelial cells, Staph. aureus and the potential effects of antimicrobials on the immune system. The results of this study confirmed that tylosin has good antimicrobial activity against both intracellular and extracellular Staph. aureus in bovine MGEC without affecting cell functions. In this study, a significant down-regulation of IL-1 and IL-6 was observed, while TNF and IL-8 expression rate numerically increased, but differences were not significant. To our knowledge, this is the first paper assessing the concentration of two lysosomal enzymes, lysozyme and N-acetyl-ß-d-glucosaminidase (NAGase), in Staph. aureus-stimulated MGEC. The results of this study confirmed that tylosin could have a significant effect on the release of these enzymes. Moreover, even if both enzymes have a similar substrate as a target, the results suggest different secretion mechanisms and an influence of antimicrobial treatment on these mechanisms. Successful mastitis cure is the result of achieving the optimal efficiency of both innate immune defences and therapeutical activities, by means of killing bacteria without eliciting an excessive inflammatory response. Therefore, antimicrobials for mastitis therapy should be selected not only on bacterial sensitivity, but also for their positive interactions with the innate immune response of the mammary gland. This study showed that an in-vitro model based on Staph. aureus challenge on MGEC could be helpful in assessing both the intracellular and extracellular activity of antimicrobials and their influence on epithelial cell immune and inflammatory response.


Assuntos
Antibacterianos/farmacologia , Células Epiteliais/efeitos dos fármacos , Imunidade Celular/efeitos dos fármacos , Inflamação/microbiologia , Staphylococcus aureus/fisiologia , Tilosina/farmacologia , Animais , Bovinos , Linhagem Celular , Relação Dose-Resposta a Droga , Células Epiteliais/imunologia , Células Epiteliais/microbiologia , Feminino , Inflamação/imunologia , Glândulas Mamárias Animais/citologia , Staphylococcus aureus/efeitos dos fármacos , Staphylococcus aureus/imunologia
4.
Microb Drug Resist ; 15(4): 239-44, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19857128

RESUMO

To examine the development of macrolide resistance in Campylobacter jejuni and assess the fitness of the macrolide-resistant mutants, two macrolide-susceptible C. jejuni strains, American Type Culture Collection (ATCC) 33291 and H1, from different geographic areas were exposed to tylosin in vitro. Multiple mutant strains were obtained from the selection. Most of the high-level macrolide-resistant strains derived from the selection exhibited the A2074C transversion in all three copies of 23S rRNA and displayed strong stability in the absence of antibiotic selection pressure. The competition experiments demonstrated that the strains containing the A2074C transversion imposed a fitness cost in competition mixtures. In addition, the fitness cost of the mutation was not ameliorated after approximately 500 generations of evolution under laboratory conditions. These findings indicate that the A2074C transversion in C. jejuni is not only correlated with stable and high-level macrolide resistance but also associated with a fitness cost.


Assuntos
Antibacterianos/farmacologia , Campylobacter jejuni/efeitos dos fármacos , Farmacorresistência Bacteriana/genética , Macrolídeos/farmacologia , Campylobacter jejuni/genética , Eritromicina/farmacologia , Testes de Sensibilidade Microbiana , Mutação , RNA Bacteriano/genética , RNA Ribossômico 23S/genética , Tilosina/farmacologia
5.
Poult Sci ; 88(10): 2118-24, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19762865

RESUMO

The effect of tilmicosin, florfenicol, or enrofloxacin on humoral and cell-mediated immune response induced by Newcastle disease (ND) vaccination was evaluated in 20-wk-old specific-pathogen-free layer chickens. Humoral immunity was measured by detection of ND virus (NDV) antibody titer and anti-NDV IgG response using the hemagglutination inhibition (HI) test and ELISA, respectively, whereas cell-mediated immunity was evaluated by measurement of chicken interferon gamma (ChIFN-gamma) produced in splenocytes cell culture stimulated with concanavalin A, inactivated NDV antigen, or live attenuated La Sota strain using ELISA. Florfenicol hampered the ND antibody production measured by both HI and ELISA. Tilmicosin and enrofloxacin reduced the production of ND antibody in the first 3 wk after the last ND vaccination measured by HI test, which suggests that these antibiotics exert their effect mainly on the IgM isotype. The ND-vaccinated, but not treated group, showed an increase in ChIFN-gamma production after NDV antigen-specific stimulation above the nonstimulated cell culture, whereas this effect was masked in all the antibiotic-treated groups due to the stronger ChIFN-gamma production background value reported in the nonstimulated cell culture. In conclusion, our results showed, for the first time, that tilmicosin, florfenicol, or enrofloxacin reduced the humoral immune response and had beneficial effects on the cell-mediated immune response. In addition, we demonstrated that the combination of both inactivated and attenuated ND vaccine gave a strong immune response at both the humoral and cellular level.


Assuntos
Antibacterianos/farmacologia , Formação de Anticorpos/imunologia , Galinhas , Imunidade Celular/imunologia , Doença de Newcastle/imunologia , Vírus da Doença de Newcastle/imunologia , Animais , Anticorpos Antivirais/sangue , Formação de Anticorpos/efeitos dos fármacos , Enrofloxacina , Ensaio de Imunoadsorção Enzimática/veterinária , Feminino , Fluoroquinolonas/farmacologia , Testes de Inibição da Hemaglutinação/veterinária , Imunidade Celular/efeitos dos fármacos , Interferon gama/sangue , Doença de Newcastle/virologia , Organismos Livres de Patógenos Específicos , Tianfenicol/análogos & derivados , Tianfenicol/farmacologia , Tilosina/análogos & derivados , Tilosina/farmacologia
6.
Vet Ther ; 9(4): 291-7, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-19177334

RESUMO

The purpose of this study was to compare the efficacy and cost-effectiveness of tilmicosin (MIC) versus tulathromycin (DRAX) as a metaphylactic antimicrobial in feedlot calves at moderate risk for bovine respiratory disease (BRD). Calves that received DRAX had significantly (P < or = .05) lower initial BRD treatment rates compared with calves that received MIC. However, there were no significant differences in the BRD relapse rate, railer rate, total mortality rate, BRD mortality rate, average daily gain, and dry matter conversion between the two groups. The economic advantage of the MIC group was Can$8.29/animal. Based on these results, while DRAX was more efficacious in reducing initial treatments for BRD in feedlot calves at moderate risk for disease, MIC was more cost-effective. The lower initial BRD treatment costs in the DRAX group did not offset the higher metaphylactic cost of DRAX.


Assuntos
Antibacterianos/farmacologia , Complexo Respiratório Bovino/prevenção & controle , Dissacarídeos/farmacologia , Compostos Heterocíclicos/farmacologia , Tilosina/análogos & derivados , Ração Animal , Animais , Animais Recém-Nascidos , Antibacterianos/economia , Complexo Respiratório Bovino/epidemiologia , Complexo Respiratório Bovino/mortalidade , Bovinos , Análise Custo-Benefício , Dissacarídeos/economia , Feminino , Compostos Heterocíclicos/economia , Distribuição Aleatória , Resultado do Tratamento , Tilosina/economia , Tilosina/farmacologia , Aumento de Peso
7.
Can J Vet Res ; 69(2): 146-50, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15971680

RESUMO

The aim of this study was to evaluate the efficacy of in-feed medication with tilmicosin phosphate in order to eliminate or reduce the carriage of Actinobacillus pleuropneumoniae in the tonsils of carrier pigs. Two groups of 6 carrier animals received either a non-medicated feed (control group) or feed medicated with 400 ppm of tilmicosin phosphate (treated group) for 30 d. Three sentinel pigs were then introduced in each group and left for 29 d. The presence of A. pleuropneumoniae in tonsils was monitored using several techniques, including polymerase chain reaction (PCR). At the end of the treatment all of the control animals, but only 1 treated pig, were positive by PCR from tonsillar surface material. However, at necropsy, all control and most treated animals, as well as 1 sentinel animal, in both groups were positive by PCR from whole tonsils. In conclusion, under the experimental conditions, in-feed treatment with 400 ppm of tilmicosin phosphate significantly reduced the presence of A. pleuropneumoniae on the surface of tonsils but was unable to completely eliminate the organism from deeper tonsillar tissues and to prevent bacterial shedding by carrier animals.


Assuntos
Infecções por Actinobacillus/veterinária , Actinobacillus pleuropneumoniae/efeitos dos fármacos , Antibacterianos/uso terapêutico , Portador Sadio/veterinária , Macrolídeos/uso terapêutico , Doenças dos Suínos/tratamento farmacológico , Tilosina/análogos & derivados , Tilosina/uso terapêutico , Infecções por Actinobacillus/tratamento farmacológico , Infecções por Actinobacillus/prevenção & controle , Actinobacillus pleuropneumoniae/crescimento & desenvolvimento , Animais , Antibacterianos/farmacologia , Portador Sadio/tratamento farmacológico , Portador Sadio/prevenção & controle , Macrolídeos/farmacologia , Tonsila Palatina/microbiologia , Distribuição Aleatória , Suínos , Doenças dos Suínos/prevenção & controle , Resultado do Tratamento , Tilosina/farmacologia
8.
Proc Natl Acad Sci U S A ; 102(14): 5180-5, 2005 Apr 05.
Artigo em Inglês | MEDLINE | ID: mdl-15795375

RESUMO

The 23S rRNA A2058G alteration mediates macrolide, lincosamide, and streptogramin B resistance in the bacterial domain and determines the selectivity of macrolide antibiotics for eubacterial ribosomes, as opposed to eukaryotic ribosomes. However, this mutation is associated with a disparate resistance phenotype: It confers high-level resistance to ketolides in mycobacteria but only marginally affects ketolide susceptibility in streptococci. We used site-directed mutagenesis of nucleotides within domain V of 23S rRNA to study the molecular basis for this disparity. We show that mutational alteration of the polymorphic 2057-2611 base pair from A-U to G-C in isogenic mutants of Mycobacterium smegmatis significantly affects susceptibility to ketolides but does not influence susceptibility to other macrolide antibiotics. In addition, we provide evidence that the 2057-2611 polymorphism determines the fitness cost of the 23S rRNA A2058G resistance mutation. Supported by structural analysis, our results indicate that polymorphic nucleotides mediate the disparate phenotype of genotypically identical resistance mutations and provide an explanation for the large species differences in the epidemiology of defined drug resistance mutations.


Assuntos
Mycobacterium smegmatis/efeitos dos fármacos , Mycobacterium smegmatis/genética , Mutação Puntual , RNA Bacteriano/genética , RNA Ribossômico 23S/genética , Sequência de Bases , Sítios de Ligação/genética , Claritromicina/farmacologia , Farmacorresistência Bacteriana/genética , Cetolídeos/química , Cetolídeos/farmacologia , Macrolídeos/química , Macrolídeos/farmacologia , Modelos Moleculares , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Conformação de Ácido Nucleico , Fenótipo , RNA Bacteriano/química , RNA Ribossômico 23S/química , Especificidade da Espécie , Tilosina/farmacologia
9.
Probl Khig ; 22: 70-9, 1997.
Artigo em Búlgaro | MEDLINE | ID: mdl-10202771

RESUMO

Tylosin-specific lymphocyte proliferation in vitro and its restriction of HLA class II antigens have been investigated in 21 allergic workers exposed to tylosin. Nine workers from tylosin industry without allergic symptoms and five nonexposed nonallergic subjects served as controls. The results showed a significantly higher lymphocyte proliferative response to tylosin in allergic workers compared to control groups. Lymphocyte proliferation was observed in five workers with allergic complaints but negative skin tests. The tylosin concentration leading to maximal proliferative response varied from 10 to 1000 micrograms/ml among individuals. Six from seven workers with maximal response to the lowest concentration of tylosin carried HLA-DQ2 antigen. Lymphocyte from most control subjects did not respond in vitro to tylosin. Weak proliferative response to tylosin was observed in two workers without clinical symptoms of allergy. No association was found between lymphocyte reactivity to PHA and tylosin in the three studied groups. In conclusion, tylosin leads to a specific activation of T lymphocytes in occupationally sensitized workers. Possibly, the T cell recognition of the hapten/protein complex is restricted by HLA-DQ2 antigen in tylosin occupational allergy. Lymphocyte stimulation test can be used for the diagnosis of tylosin occupational allergy, as well as for the detection of latently sensitized workers.


Assuntos
Antibacterianos/farmacologia , Hipersensibilidade a Drogas/sangue , Leucócitos Mononucleares/efeitos dos fármacos , Doenças Profissionais/sangue , Tilosina/farmacologia , Adulto , Antibacterianos/efeitos adversos , Bulgária , Divisão Celular/efeitos dos fármacos , Células Cultivadas , Hipersensibilidade a Drogas/etiologia , Indústria Farmacêutica , Feminino , Antígenos HLA/sangue , Antígenos HLA/efeitos dos fármacos , Humanos , Leucócitos Mononucleares/citologia , Masculino , Doenças Profissionais/induzido quimicamente , Estatísticas não Paramétricas , Linfócitos T/citologia , Linfócitos T/efeitos dos fármacos , Tilosina/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA